Surgical Science Sweden AB (publ) (SUSRF)
| Market Cap | 318.61M -25.8% |
| Revenue (ttm) | 105.50M +8.4% |
| Net Income | 9.61M +0.7% |
| EPS | 0.19 +0.6% |
| Shares Out | n/a |
| PE Ratio | 29.48 |
| Forward PE | 22.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Open | 5.48 |
| Previous Close | 5.20 |
| Day's Range | 5.48 - 5.48 |
| 52-Week Range | 2.84 - 8.93 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About SUSRF
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnosti... [Read more]
Financial Performance
In 2025, SUSRF's revenue was 992.34 million, an increase of 12.25% compared to the previous year's 884.09 million. Earnings were 66.82 million, a decrease of -49.24%.
Financial numbers in SEK Financial StatementsNews
Surgical Science Sweden AB Earnings Call Transcript: Q2 2026
Q2 2026 saw 22% revenue growth and a 15% adjusted EBIT margin, with strong license revenues and gross margin improvement. All segments and regions contributed, especially ultrasound and educational products, while operational investments and price increases are set to further boost performance.
Surgical Science Sweden AB Quarterly report: Q2 2026
Surgical Science Sweden AB has published its Q2 2026 quarterly earnings report on August 19, 2026.
Surgical Science Sweden AB Slides: Q2 2026
Surgical Science Sweden AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 19, 2026.
Surgical Science upgraded to Buy from Hold at Berenberg
Berenberg upgraded Surgical Science (SUSRF) to Buy from Hold with a SEK 45 price target The business is positioned for improvement while the shares are “priced for failure,” the analyst…
Surgical Science Sweden AB Earnings Call Transcript: Q1 2026
Q1 2026 saw underlying growth and strong cash flow despite a 6% reported sales decline due to FX headwinds. EMEA and UK delivered standout results, new product launches advanced the portfolio, and the company remains on track for its 2027 targets.
Surgical Science Sweden AB Quarterly report: Q1 2026
Surgical Science Sweden AB has published its Q1 2026 quarterly earnings report on May 20, 2026.
Surgical Science Sweden AB Slides: Q1 2026
Surgical Science Sweden AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 20, 2026.
Surgical Science Sweden AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 15% local currency sales growth and record license revenues, though currency headwinds and a contract change with Intuitive will impact 2026. Operational efficiency improved, with cost savings realized and new products launched, supporting a positive long-term outlook.
Surgical Science Sweden AB Quarterly report: Q4 2025
Surgical Science Sweden AB has published its Q4 2025 quarterly earnings report on February 19, 2026.
Surgical Science Sweden AB Slides: Q4 2025
Surgical Science Sweden AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
Surgical Science Sweden AB Annual report: Q4 2025
Surgical Science Sweden AB has published its Q4 2025 annual report on February 19, 2026.
Surgical Science Sweden AB Transcript: CMD 2025
A new strategy targets five business segments, aiming for 10%-15% annual revenue growth and at least 15% Adjusted EBIT by 2027. Profitability improvements, product innovation, and expanded sales channels are central, with a planned move to the Nasdaq Main Market to broaden investor access.
Surgical Science Sweden AB Press release: FY 2025
Surgical Science Sweden AB issued a press release on December 8, 2025, disclosing material business information to investors.
Surgical Science Sweden AB Slides: FY 2025
Surgical Science Sweden AB has posted slides in relation to its FY 2025 quarterly earnings report, which was published on December 8, 2025.
Surgical Science price target lowered to SEK 40 from SEK 120 at Berenberg
Berenberg analyst Simon Jonsson lowered the firm’s price target on Surgical Science (SUSRF) to SEK 40 from SEK 120 and keeps a Hold rating on the shares. Published first on…
Surgical Science Sweden AB Earnings Call Transcript: Q3 2025
Q3 2025 delivered record sales and improved profitability initiatives, with strong growth in Europe and Industry OEM, but margin pressure from currency and product mix. Robotics and ultrasound segments show high demand, while U.K. and U.S. markets remain challenging.
Surgical Science Sweden AB Quarterly report: Q3 2025
Surgical Science Sweden AB has published its Q3 2025 quarterly earnings report on November 13, 2025.
Surgical Science Sweden AB Slides: Q3 2025
Surgical Science Sweden AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.